bluebird bio (NASDAQ:BLUE) reported quarterly sales of $18.600 million which missed the analyst consensus estimate of $19.551 million by 4.86 percent. This is a 681.18 percent increase over sales of $2.381 million the same period last year.
bluebird bio (NASDAQ:BLUE) reported quarterly sales of $18.600 million which missed the analyst consensus estimate of $19.551 million by 4.86 percent. This is a 681.18 percent increase over sales of $2.381 million the same period last year.
Comments